Infections, malignancy risk in IBD must be considered individually

MAUI, Hawaii — Certain inflammatory bowel disease therapies may further increase malignancies in patients with Crohn’s disease or ulcerative colitis, according to an expert at the GUILD Conference 2020.“We need to think about each individual patient as different with different characteristics and different individual risk factors,” Millie D. Long, MD, MPH, associate professor of medicine, vice chief for education and director of the gastroenterology and hepatology fellowship program at the Inflammatory Bowel Diseases Center at the University of North Carolina-ChapelRead More

Share on facebook
Share on twitter
Share on linkedin